RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc. (NASDAQ: LPDX) an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data from two studies, at the Annual Scientific Session of the American College of Cardiology (ACC) in San Francisco, highlighting the importance of low density lipoprotein particle (LDL-P) measurements in identifying cardiovascular disease risk for patients. Previous studies have indicated that many patients with relatively normal levels of low density lipoprotein cholesterol (LDL-C) have increased LDL-P, illustrating discordance between the two measures of LDL. The medical community is increasingly aware of the critical role utilizing LDL-P as measured by nuclear magnetic resonance (NMR) spectroscopy to help manage a patient’s cardiovascular disease risk. The data presented at ACC further validates the need for increased awareness of LDL-P as an indicator of cardiovascular disease, and the value of NMR as a differentiated platform technology.